UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
| Registry | NCT04134468 |
|---|---|
| Status | Withdrawn - Halozyme halted development of PEGPH20 following Phase 3 failure. |
| Phase | Phase 2 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Sponsor | Abramson Cancer Center at Penn Medicine (Other); collaborators: Halozyme Therapeutics |
| Conditions | Pancreatic Ductal Adenocarcinoma |
| Interventions | Pegvorhyaluronidase alfa, Abraxane, Gemcitabine (Drug) |
| Dates | start 2020-01-01 (estimated), primary completion 2021-02-11 (estimated), completion 2022-11-11 (estimated), first posted 2019-10-22, last updated 2020-01-31 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Pancreatic Ductal Adenocarcinoma All trials of Pegvorhyaluronidase alfa All trials of Abraxane
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will received Gemcitabine, Abraxane and PEGPH20.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine | Experimental | Drug: Pegvorhyaluronidase alfa; Drug: Abraxane; Drug: Gemcitabine | Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: 1. Signed Informed Consent Form 2. Capable of giving informed consent. 3. Ability and willingness to comply with the protocol including all scheduled MRI studies and paired tumor biopsies 4. Aged ≥ 18 years. 5. borderline or unresectable pancreatic adenocarcinoma without distant metastatic disease. 6. ECOG PS of 0 or 1 7. Must have adequate organ and hematopoietic function 8. Female and Males must use an approved contraceptive method Exclusion Criteria: 1. Received prior therapy for pancreatic adenocarcinoma 2. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) 3. Contraindication to therapeutic anticoagulation or heparin 4. Intolerance to dexamethasone 5. Contraindication to MRI or unwillingness to undergo all scheduled MRI exams 6. Known or suspected brain metastasis 7. Significant cardiovascular disease such as current New York Heart Associate Class III/IV heart failure, myocardial infarction or stroke within 6 months prior to enrollment 8. A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results 9. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint 10. Active bacterial or fungal infection requiring IV therapy at the start of protocol treatment 11. Subjects may not receive concomitant anticancer agents or radiation. 12. Female subjects who are pregnant or nursing 13. Pre-existing peripheral neuropathy > CTCAE Grade 2. 14. Known allergy to hyaluronidase 15. Current use of megestrol acetate (use within 10 days of Day 1) 16. Inability to comply with study and follow-up procedures as judged by the Investigator
| Facility | City | Country | Status |
|---|---|---|---|
| Abramson Cancer Center at University of Pennsylvania | Philadelphia, Pennsylvania | United States |